
Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products
Wenbo Sai, Dongchen Jia, Hao Chen, Wei Wei
Engineering ›› 2024, Vol. 32 ›› Issue (1) : 14-17.
Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products
[[1]] |
ICH Harmonised Tripartite Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1999 Sep 23 [cited 2023 Aug 13].
|
[[2]] |
ICH Harmonised Guideline.Technical and regulatory considerations for pharmaceutical product lifecycle management Q12 [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2017 Nov 16 [cited 2023 Aug 13].
|
[[3]] |
|
[[4]] |
|
[[5]] |
|
[[6]] |
ICH Harmonised Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R2) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2022 Sep 29 [cited 2023 Aug 13].
|
[[7]] |
|
[[8]] |
|
[[9]] |
|
[[10]] |
|
[[11]] |
|
[[12]] |
|
[[13]] |
|
[[14]] |
|
/
〈 |
|
〉 |